Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D07BGC
|
|||
| Former ID |
DIB000718
|
|||
| Drug Name |
GDC-0084
|
|||
| Synonyms |
GDC-0084/RG7666
Click to Show/Hide
|
|||
| Indication | Glioblastoma of brain [ICD-11: 2A00.00; ICD-10: C71] | Phase 2 | [1] | |
| Company |
Genentech
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C18H22N8O2
|
|||
| Canonical SMILES |
CC1(C2=NC3=C(N2CCO1)N=C(N=C3N4CCOCC4)C5=CN=C(N=C5)N)C
|
|||
| InChI |
1S/C18H22N8O2/c1-18(2)16-22-12-14(25-3-6-27-7-4-25)23-13(11-9-20-17(19)21-10-11)24-15(12)26(16)5-8-28-18/h9-10H,3-8H2,1-2H3,(H2,19,20,21)
|
|||
| InChIKey |
LGWACEZVCMBSKW-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 1382979-44-3
|
|||
| PubChem Compound ID | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT03522298) Safety, Pharmacokinetics and Efficacy of Paxalisib (GDC-0084) in Newly-diagnosed Glioblastoma. U.S. National Institutes of Health. | |||
| REF 2 | Current clinical development of PI3K pathway inhibitors in glioblastoma. Neuro Oncol. 2012 July; 14(7): 819-829. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.